Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988070 | 0.92 | KDR (0.37) | PPARAEPHX2NR1H4 | |
| SCHEMBL4864961 | 0.92 | SCD (0.42) | EPHX2NR1H4 | |
| SCHEMBL4990330 | 0.88 | KDR (0.38) | PPARAPPARGPPARDEPHX2 | |
| SCHEMBL4988571 | 0.88 | AOC3 (0.45) | EPHX2NR1H4CHRM4 | |
| SCHEMBL4991261 | 0.88 | PPARA (0.42) | PPARADYRK1A | |
| SCHEMBL4986159 | 0.87 | AOC3 (0.37) | — | |
| SCHEMBL4985026 | 0.86 | ALDH1A1 (0.44) | CHRM4 | |
| SCHEMBL4871385 | 0.86 | AOC3 (0.41) | — | |
| SCHEMBL4986016 | 0.85 | AOC3 (0.36) | — | |
| SCHEMBL4876799 | 0.85 | PPARA (0.47) | PPARAPPARGPPARDEPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | PPARA 2346/4885PPARG 2414/4885PPARD 2704/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | PPARA 664/4885PPARG 867/4885PPARD 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.